Biolase, Inc. · OTC:BIOLQ
Biolase — LD Micro Main Event 2016
23 slides from Biolase's conference presentation, Dec 7, 2016
Slide 1: World Leader in Dental Lasers
World Leader in Dental Lasers Transformational Technology Enabling Better Patient Outcomes NASDAQ CM:BIOL December 2016 Exhibit 99.1
Slide 2: Safe Harbor Statement
Statements made during BIOLASE’s presentation and in its representative’s answers to questions at the LD Micro’s Main Event conference (the “Conference”) that refer to BIOLASE’s estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statement
Slide 3: Investment Thesis
Disrupting dentistry through transformational technology and products, world class education: Turnaround – continuing revenue and profit growth with focus on commercial execution, international performance/expansion, superlative education Strategic pivot to focus on high-value, prevalent and undertr
Slide 4: Experienced Leadership team enables continued progress and transformation of BIOLASE
Experienced Leadership team enables continued progress and transformation of BIOLASE Harold C. Flynn, Jr. President & CEO David Dreyer Chief Financial Officer Michael Roux Vice President, Marketing Dmitri Boutoussov Chief Technology Officer Richard Whipp Vice President, Operations Joseph Rotino Vice
Slide 5: New & Expanding Leadership
Broad experience in dentistry, medical lasers, medical device and pharma companies; from start-ups to Fortune 100 companies New CEO, July 2015; Led Zimmer Dental for eight years Introduced transformational products; developed world’s leading dental regenerative portfolio Executed international M&A;
Slide 6: High Level Plan
High Level Plan Key Strategic Priorities Goals Build Talent & Team, Shape Healthy High-Performance Culture Drive Commercial Execution & Channel Excellence US EMEA ROW Delight the customer – customer service build out and support excellence Elevate Training and Education & Educator/Opinion Leader sta
Slide 7: 3 imperatives to disrupt dentistry and establish All-Tissue Laser Dentistry as the Standard of Care
SHAKE COMPLACENCY - Get complacent dentists around the world to perform procedures with lasers that they may be afraid of doing and uncomfortable presenting(selling) to patients…help make every dentist a better dentist EDUCATE TO HIGH COMPETENCE – Ensure great results with simple to use and versatil
Slide 8: Laser Dentistry addresses challenges facing today's dentists
Laser Dentistry addresses challenges facing today’s dentists as described by the ADA, CDC, other professional organizations Seeking Better Patient Reported Outcomes With More Competition, Less Busy and Become Bored Missing Opportunity To Treat Earlier and Make More Money Average Pay Decreasing Over
Slide 9: Significant Growth Opportunity: gum disease
More than 60,000,000 people have gum disease, and health risk of oral-systemic connection in U.S. alone Under-diagnosed, Under-treated, Under-managed Waterlase iPlus Home Screen Significant Growth Opportunity
Slide 10: Patient Benefits: Better Outcomes & Less…
Patient Benefits: Better Outcomes & Less… Minimally Invasive Dental Microsurgery
Slide 11: Dentist Benefits: Better Outcomes & More…
Dentist Benefits: Better Outcomes & More… Minimally Invasive Dental Microsurgery
Slide 12: New diode dental laser and laser portfolio
New! – Most powerful and capable diode dental laser ever Best in class speed, comfort, and precision cutting FDA 510(k) pending Leverages IPG Medical technology A growing full-spectrum portfolio of laser systems and procedural consumables World’s Best selling All-Tissue dental laser- 80 FDA Cleared
Slide 13: Moving to a "Whole Product" approach to address Pragmatists
Moving to a “Whole Product” approach to successfully address Pragmatists Differentiated “value tiered” product portfolio to access and expand more markets Pivoting strategy to widely prevalent yet under-treated diseases Development of alternative business models and pricing strategies BIOLASE poised
Slide 14: US Dental market opportunity for All-Tissue lasers
The US Dental market has significant remaining opportunity for All-Tissue lasers to penetrate clinics Improved Patient Reported Outcomes High prevalence, under-treated conditions High Volume Procedures THE OPPORTUNITY ADDRESSABLE MARKET TARGET MARKET SERVED UNSERVED 97,009 72,758 6,700 66,058 75% of
Slide 15: Global All-Tissue penetration at ~5%
Global All-Tissue penetration at ~5% reinforces “The Chasm” not yet crossed to the early majority – significant opportunity exists High Volume Procedures Improved Clinical Outcomes Evidence-based THE OPPORTUNITY ADDRESSABLE MARKET TARGET MARKET SERVED UNSERVED 606,116 403,678 18,200 385,477 Sources:
Slide 16: Dominant share in All-Tissue laser markets
BIOLASE positioned well with dominant share in All-Tissue laser markets and market leadership in Soft-Tissue lasers Soft Tissue Lasers Global Share All Tissue Lasers Global Share The majority of lasers sold are Soft Tissue devices. However, Biolase commands a dominant or significant share in both ma
Slide 17: Historical market revenue trends and CAGR potential
Historical market revenue trends achieved mid to high single digit CAGR – BIOLASE can achieve > 15% CAGR over next 5 years (000s) Sources: iData Research 2014 reports; MarketMarkets Research 2015; industry and anecdotal reports. All Tissue Laser Market - Global Soft Tissue Laser Market - Global Tota
Slide 18: Two-thirds of 2015 revenue from laser system sales
Two-thirds of 2015 revenue came from laser system sales and 55% the sales were made in the U.S. – significant opportunity in bringing Europe “on par” with U.S. United States 55% International 45%
Slide 19: Financial Highlights: Selected Income Statement Data
($ IN THOUSANDS) Q3 2016 Q3 2015 % Delta YTD 2016 YTD 2015 % Delta Net Revenue 13,229 11,234 17.8 38,049 33,958 12.0 Cost of Revenue 7,624 7,853 -2.9 23,144 23,666 -2.2 Gross Profit 5,605 3,381 65.8 14,905 10,292 44.8 Total Operating Expenses 8,753 8,733 0.2 25,753 27,932 -7.8 GAAP Net Loss (3,146)
Slide 20: Financial Highlights: Selected Balance Sheet Data
($ IN THOUSANDS) September 30, 2016 (Unaudited) December 31, 2015 (Audited) Change % Cash & Cash Equivalents 12,650 11,699 951 8.1 Accounts Receivable 9,938 8,948 990 11.1 Inventory 13,543 12,566 977 7.8 Total Current Assets 37,277 34,800 2,477 7.1 Total Assets 44,619 42,251 2,368 5.6 Total Current
Slide 21: BIOLASE Stock Data
BIOLASE Stock Data: (NASDAQ:BIOL) - 1 Year 52 Week Price Range $0.65 - $1.98 Recent Price (December 5, 2016) $1.78 Average Daily Volume (3 month) 77,379 Common Shares Outstanding (December 5, 2016) 67,565,951 Market Capitalization (December 5, 2016) $120,267,393
Slide 22: Summary
World leader in dental laser systems having sold >32,000 dental laser systems Veteran top management team with successful dental industry and medical device experience leading the turnaround and transformation of BIOLASE Disrupting dentistry establishing new standards of care for under-managed disea
Slide 23: Questions and Answers
Questions and Answers ee OE